文献速递胃肠动力与功能性疾病

曲地匹坦治疗糖尿病性和特发性胃轻瘫患者的随机安慰剂对照试验中的疗效与安全性

Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial.
PubMed 文献 · Gastroenterology · 2020-07-18

该双盲试验纳入美国47个中心的152例特发性或糖尿病性胃轻瘫成人患者,随机接受口服曲地匹坦85 mg(n=77)或安慰剂(n=75)每日两次共4周。曲地匹坦组第4周恶心评分降低1.2,安慰剂组降低0.7(P=.0099);无恶心天数增加28.8% vs 15.0%(P=.0160);基线有恶心呕吐者中曲地匹坦组恶心降低1.4 vs 安慰剂组0.4(P<.0001),无恶心天数改善32.3% vs 7.6%(P=.0003)。

要点

  • 曲地匹坦85 mg每日两次治疗4周可改善特发性或糖尿病性胃轻瘫患者的恶心症状。
  • 基线有恶心呕吐的患者中曲地匹坦的疗效更明显(恶心评分降低1.4 vs 0.4)。
  • 曲地匹坦组46.6%患者胃轻瘫主要症状指数评分改善超过1分,安慰剂组为23.5%。

核心结论

  • 在特发性或糖尿病性胃轻瘫患者中,与安慰剂相比,曲地匹坦在恶心和呕吐方面取得了具有统计学和临床意义的改善。

研究设计与样本

  • 双盲试验,2016年11月至2018年12月在美国47个中心纳入152例胃轻瘫成人患者。
  • 参与者随机接受口服曲地匹坦85 mg(n=77)或安慰剂(n=75)每日两次,共4周。
  • 主要结局为意向性治疗分析中胃轻瘫核心症状日记所测平均恶心严重程度从基线至第4周的变化。

主要发现

  • 曲地匹坦组第4周恶心评分降低1.2,安慰剂组降低0.7(P=.0099)。
  • 曲地匹坦组第4周无恶心天数增加28.8%,安慰剂组增加15.0%(P=.0160)。
  • 基线有恶心呕吐者(n=101)中,曲地匹坦组恶心降低1.4,安慰剂组降低0.4(P<.0001)。
  • 基线有恶心呕吐者中,曲地匹坦组第4周无恶心天数改善32.3%,安慰剂组改善7.6%(P=.0003)。
  • 第4周平均恶心评分≤1分的患者比例:曲地匹坦组32.9%,安慰剂组11.8%(P=.0013);胃轻瘫主要症状指数评分改善超过1分的比例:曲地匹坦组46.6%,安慰剂组23.5%(P=.0053)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatments are needed for gastroparesis; antagonists of tachykinin receptor 1 (TACR1, also called NK1R) can reduce symptoms of nausea and vomiting. We investigated the safety and efficacy of tradipitant, an antagonist of NK1R, in patients with idiopathic or diabetic gastroparesis. METHODS: We performed a double-blind trial of 152 adults with gastroparesis at 47 sites in the United States from November 2016 through December 2018. Participants were randomly assigned to groups given oral tradipitant 85 mg (n = 77) or placebo (n = 75) twice daily for 4 weeks. Symptoms were assessed by a daily symptom dairy, Gastroparesis Cardinal Symptom Index scores, and other patient-reported questionnaires. The primary outcome from the intent-to-treat analysis was change from baseline to week 4 in average nausea severity, measured by the Gastroparesis Core Symptom Daily Diary. RESULTS: Patients receiving tradipitant had a significant decrease in nausea score (reduction of 1.2) at week 4 compared with placebo (reduction of 0.7) (P = .0099) and a significant increase in of nausea-free days at week 4 (28.8% increase on tradipitant vs 15.0% on placebo; P = .0160). Patients with nausea and vomiting at baseline (n = 101) had an even greater decrease in nausea in when given tradipitant (reduction of 1.4) compared with those given placebo (reduction of 0.4) (P < .0001), as well as an increase in nausea-free days at week 4 (32.3% improvement on tradipitant vs 7.6% on placebo; P = .0003). The average nausea score was 1 or less at week 4 in 32.9% of patients given tradipitant compared with 11.8% of patients given placebo (P = .0013). A greater than 1-point improvement in Gastroparesis Cardinal Symptom Index score was observed in 46.6% of patients given tradipitant compared with 23.5% of patients given placebo (P = .0053). CONCLUSIONS: Tradipitant resulted in statistically and clinically meaningful improvements in nausea and reduced vomiting, compared with placebo, in patients with idiopathic or diabetic gastroparesis. ClinicalTrials.gov, Number: NCT02970968.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Carlin JL, Lieberman VR, Dahal A, et al. Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. Gastroenterology. 2020. PMID: 32693185. doi:10.1053/j.gastro.2020.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。